These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18468564)

  • 21. Strategies and impacts of new drug introduction: hemophilia treatment.
    Guirguis HS; Rogoff EG
    J Health Care Finance; 2004; 31(1):1-12. PubMed ID: 15816224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
    Gorlin DI
    Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
    [No Abstract]   [Full Text] [Related]  

  • 23. The year's new drugs and biologics--2007.
    Graul AI; Prous JR; Barrionuevo M; Bozzo J; Castaner R; Cruces E; Revel L; Rosa E; Serradell N; Sorbera LA
    Drug News Perspect; 2008; 21(1):7-35. PubMed ID: 18301807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Handing over the baton: connecting medicinal chemistry with process R&D.
    Federsel HJ
    Drug News Perspect; 2008 May; 21(4):193-9. PubMed ID: 18560618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of erectile dysfunction after cancer treatment.
    Peltier A; van Velthoven R; Roumeguère T
    Curr Opin Oncol; 2009 Jul; 21(4):303-9. PubMed ID: 19509501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Once daily therapy of erectile dysfunction. "Flexible love life without time constraints"].
    Porst H
    MMW Fortschr Med; 2009 Jun; 151(23):55. PubMed ID: 19591357
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugs, industry, and academia.
    Fitzgerald GA
    Science; 2008 Jun; 320(5883):1563. PubMed ID: 18566251
    [No Abstract]   [Full Text] [Related]  

  • 29. A review of the effect of pharmaceutical firm drug announcements on stock option pricing.
    Younis MM; Younies H; Kisa A; Hartmann M; Hussain AA; Al-Amro A
    J Health Care Finance; 2009; 35(3):35-43. PubMed ID: 19891206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 31. [Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study].
    Mazo EB; Gamidov SI; Iremashvili VV; Gasanov RV
    Urologiia; 2009; (1):40, 43-6. PubMed ID: 19432232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward biosimilar monoclonal antibodies.
    Schneider CK; Kalinke U
    Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
    [No Abstract]   [Full Text] [Related]  

  • 33. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases.
    Ioannides D; Lazaridou E; Apalla Z; Devliotou-Panagiotidou D
    Br J Dermatol; 2009 Mar; 160(3):719-20. PubMed ID: 19175601
    [No Abstract]   [Full Text] [Related]  

  • 35. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

  • 37. Rebuilding the R&D engine in big pharma.
    Garnier JP
    Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [5-phosphodiesterase inhibitors and cardiovascular risk].
    Tostain J
    Prog Urol; 2008 Dec; 18(13):1091-2. PubMed ID: 19041817
    [No Abstract]   [Full Text] [Related]  

  • 39. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure.
    Guazzi M
    Circ Heart Fail; 2008 Nov; 1(4):272-80. PubMed ID: 19808302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.